Back to search
FDAFDA · Food and drugs·Recall number Z-2531-2024

CryoValve SG Pulmonary Human Heart Valve, SGPV00, Cryopreserved Decellularized Heart Valve Allograft Prepared with SynerGraft (SG) Technology.

Published August 14, 2024 · Recall initiated: May 28, 2024

Summary

FDA records medical device Class II recall Z-2531-2024, published August 14, 2024 and initiated May 28, 2024. Recalling firm: Artivion, Inc; Status: Ongoing; Reported quantity: 2 valves; Lot: Serial #11673489, exp. 27Jan2026; and serial #12657716, exp. 15Aug2028, UDI-DI: 00877234000447. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Grafts were found to have been approved, released, shipped and implanted with an invalid test results.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Artivion, Inc
Distributor
US Nationwide distribution in the states of CA, DC, FL, and NY.
Lot
Serial #11673489, exp. 27Jan2026; and serial #12657716, exp. 15Aug2028, UDI-DI: 00877234000447
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was CryoValve SG Pulmonary Human Heart Valve, SGPV00, Cryopreserved Decellularized Heart Valve Allograft Prepared with SynerGraft (SG) Technology. recalled?

Yes. FDA published recall Z-2531-2024 on August 14, 2024. Reported hazard: Grafts were found to have been approved, released, shipped and implanted with an invalid test results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter